ReviewCurrent opinion in hematology2009
Second hematopoietic stem cell transplantation in myeloid malignancies.
Review in Current opinion in hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- Chidamide combined with decitabine, venetoclax, and low-dose cytarabine for relapsed/refractory acute myeloid leukemia: a single-center case series.Frontiers in oncology · 2026Article
- Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT.Bone marrow transplantation · 2026Article
- Second allogeneic transplantation in relapsed acute leukemia - a risk worth taking?Annals of hematology · 2025Article
- Genetic profile of ASXL1 gene in risk assessment in acute myeloid leukemia.BMC genomic data · 2025Article
- Prognostic factors of survival in second allogeneic hematopoietic transplantation.Annals of hematology · 2025Article
- Comparison of HiDAC Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome.European journal of haematology · 2025Article
- Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients.Blood cancer journal · 2024Article
- The Therapeutic Potential of a Strategy to Prevent Acute Myeloid Leukemia Stem Cell Reprogramming in Older Patients.International journal of molecular sciences · 2023Review
- Infectious complications after second allogeneic hematopoietic cell transplant in adult patients with hematological malignancies.Bone marrow transplantation · 2022Article
- Review
- Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.Annals of hematology · 2022Article
- Treatment of Relapsed Acute Myeloid Leukemia.Current treatment options in oncology · 2020Review
- Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children.Bone marrow transplantation · 2019Article
- The role of second transplants for leukemia.Best practice & research. Clinical haematology · 2016Review
- Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT.Bone marrow transplantation · 2015Article
- Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure.American journal of hematology · 2015Article
- Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Article
- Costs of second allogeneic hematopoietic cell transplantation.Transplantation · 2013Article
- Article
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2010Article
Corrections and comments
- Commented on byMyeloid disease.2009
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
purpose of reviewHematopoietic stem cell and umbilical cord blood transplantation can be a life-saving procedure for many patients with myeloid malignancies. The posttransplant period, however, can be complicated by graft failure and disease relapse, prompting the need for further therapy. Herein, we review and examine the data of second allogeneic stem cell transplant after autologous, allogeneic and umbilical cord blood transplantation. RECENT
findingsAlthough large, prospective, multicenter trials are lacking, certain factors such as younger patient age, lower disease burden and a longer interval between first transplantation and relapse appear to portend a better prognosis for second transplant. SUMMARY: Currently, only a selected group of patients without important comorbidities should be considered for second allogeneic transplantation. Strategies such as new immunosuppressive agents, antileukemia monoclonal antibodies, graft modification and use of molecularly targeted therapy are needed to decrease the morbidity and increase the efficacy of transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.